Additionally, three genes from this signature, SOCS2, NR4A2 and TNFAIP3 were found to be lower expressed in MS patients with an aggressive disease course, indicating that they might function as negative regulators of inflammation (9). This evidence concerns the gene NR4A2 and myeloid sarcoma.